Last update Sept. 4, 2021

Iloprost

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a stable analog of the prostaglandin epoprostenol (prostacyclin) with pharmacokinetics and vasodilator and antiplatelet properties similar to those of epoprostenol.
Used in peripheral vascular disorders and pulmonary hypertension.
Administration by intravenous infusion or by inhalation.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its acid pKa and large volume of distribution, as well as its very fast elimination half-life (T½ of 15 - 30 minutes) make it unlikely to pass into breast milk in significant amount.

Its low oral bioavailability (Kirsten 1998) makes it difficult for the infant to pass into plasma from ingested breast milk.

No problems were reported in a newborn breastfed by a mother treated with iloprost (Mirdamadi 2016).

It is a medication that is used in newborns, including premature (Verma 2021, Eifinger 2008).


See below the information of this related product:

  • Epoprostenol (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

  • Aspirin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Epoprostenol (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Iloprost is also known as


Iloprost in other languages or writings:

Group

Iloprost belongs to this group or family:

Tradenames

Main tradenames from several countries containing Iloprost in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 16 %
Molecular weight 361 daltons
Protein Binding 60 %
VD 0,7 l/Kg
pKa 4,66 -
Tmax 0,1 hours
T1/2 0,25 - 0,5 hours

References

  1. Verma S, Lumba R, Kazmi SH, Vaz MJ, Prakash SS, Bailey SM, Mally PV, Randis TM. Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn. Am J Perinatol. 2021 Jan 21. Abstract
  2. FDA. Iloprost trometamol (Ventavis). Drug Summary. 2021 Full text (in our servers)
  3. Mirdamadi A, Gharavi H, Behjati M. Role of Meticulous Observation: Successful Pregnancy in a 30-Year-Old Woman with Severe Pulmonary Hypertension. Tanaffos. 2016;15(3):187-190. Abstract
  4. AEMPS. Iloprost trometamol (Ilomedin). Ficha técnica. 2014 Full text (in our servers)
  5. EMA. Iloprost trometamol (Ventavis). Ficha técnica. 2013 Full text (in our servers)
  6. Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin Padiatr. 2008 Mar-Apr;220(2):66-9. Epub 2007 Aug 21. Abstract
  7. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract

Total visits

2,664

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM